Abstracts tagged "Enzyme-Linked Immunoabsorbant Assays (ELISA)"

Abstract Number: 130 • 2019 ACR/ARP Annual Meeting
Is There Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Serum and Plasma Testing in a Real-World Clinical Setting
Michael Pham¹, Giovanni Orsolini ², Cynthia Crowson ³, Melissa Snyder ¹, Rajiv Pruthi ⁴ and Kevin Moder ⁵, ¹Mayo Clinic, Rochester, MN, ²University of Verona, Verona, Italy, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic, Rochester, ⁵Mayo Clinic Rochester, rochester, MN
Background/Purpose: Traditionally in ELISA detection of APS antibodies, the use of serum is thought to be preferable over plasma according to international consensus bodies. The…
Abstract Number: 491 • 2019 ACR/ARP Annual Meeting
Diagnostic Performance of Anti-cyclic Citrullinated Peptide (CCP) 2 and CCP3.1 Assays in Early Rheumatoid Arthritis
Daniela Sieghart¹, Christian Konrad ², Sascha Swiniarski ², Helmuth Haslacher ³, Daniel Aletaha ⁴ and Günter Steiner ¹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Vienna, Austria, Vienna, Austria, ²Thermo Fisher Scientific, Freiburg, Germany, Freiburg, Germany, ³Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: Anti-cyclic citrullinated peptide (CCP) antibodies are the most specific markers for rheumatoid arthritis (RA). Different generations of assays (CCP1-CCP3) have been developed which show…
Abstract Number: 661 • 2019 ACR/ARP Annual Meeting
Association of Serum and Urine Levels of TWEAK, MCP-1 and NGAL with Disease Activity in Systemic Lupus Erythematosus
SAFAK MIRIOGLU ¹, SUZAN CINAR ², Halil Yazici ³, Ahmet Gül ⁴, Lale Öcal ⁴, Murat Inanc ⁴ and Bahar Artim-Esen⁴, ¹Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, ISTANBUL, Turkey, ²Istanbul University,Department of Immunology, Institute of Experimental Medicine, ISTANBUL, Turkey, ³Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Nephrology, Istanbul, Turkey, ⁴Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: TWEAK, MCP-1 and NGAL, mediators in pathogenesis of systemic lupus erythematosus (SLE), are proinflammatory cytokines/chemokines that are thought as potential biomarkers reflecting disease activity.…
Abstract Number: 2642 • 2019 ACR/ARP Annual Meeting
ANCA Testing: Final Diagnoses in Cases with Positive Immunofluorescence and Negative ELISA
‪Gabriel Breuer‬‏¹, Bashar Fteiha ¹, Alon Benaya ¹, Marwan Abu Sneineh‬‏ ¹ and Gideon Nesher ¹, ¹Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel
Background/Purpose: With the widespread availability of anti-neutrophil cytoplasmic antibody (ANCA) testing, interpreting positive results has become increasingly challenging. In addition to ANCA Associated Vasculitis (AAV),…
Abstract Number: 596 • 2016 ACR/ARHP Annual Meeting
Association Between Plasma Certolizumab Pegol Concentration and Improvement in Disease Activity in Rheumatoid Arthritis and Crohn’s Disease
Gerrit Wolbink^1,2, Philippe Goupille³, William Sandborn⁴, Hubert Marotte⁵, Denis Mulleman³, David Ternant³, Stéphane Paul⁵, Marc de Longueville⁶, Niels Vande Casteele^4,7, Miren Zamacona⁶, Cathy O'Brien⁶, Tore K. Kvien⁸ and Arthur F. Kavanaugh⁹, ¹Amsterdam Rheumatology Immunology Center (ARC), Reade, Amsterdam, Netherlands, ²Department of Immunopathology, Sanquin, Amsterdam, Netherlands, ³Université François-Rabelais, Tours, France, ⁴Division of Gastroenterology, UC San Diego School of Medicine, La Jolla, CA, ⁵Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France, ⁶UCB Pharma, Brussels, Belgium, ⁷KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, ⁸Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁹Division of Rheumatology, Allergy & Immunology, UC San Diego School of Medicine, La Jolla, CA
Background/Purpose: Anti-TNFs neutralize the TNF-mediated component of inflammatory diseases such as rheumatoid arthritis (RA) and Crohn’s disease (CD) to reduce disease activity. In this study,…
Abstract Number: 1073 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository Analysis: The Comparison of Real World and Core Laboratory Antiphospholipid Antibody ELISA Results
Savino Sciascia¹, Rohan Willis², Vittorio Pengo³, Steven Krilis⁴, Danieli Andrade⁵, Doruk Erkan⁶, Maria Laura Bertolaccini⁷ and On Behalf of APS ACTION .⁸, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ³Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁴Department of Immunology, Allergy and Infectious Diseases, University of New South Wales, Sydney, Australia, ⁵Rheumatology, University of Sao Paulo, Sao Paulo, Brazil, ⁶Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁷Academic Department of Vascular Surgery, King’s College London, London, United Kingdom, ⁸., New York, NY
Background/Purpose: The APS ACTION International Clinical Database and Repository (“Registry”) was created to study the natural course of disease over 10 years in persistently aPL-positive…
Abstract Number: 2589 • 2016 ACR/ARHP Annual Meeting
Comparison of Two Enzyme-Linked Immunosorbent Assays Used for Drug Concentration Monitoring in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Stéphane Paul¹, John Smeraglia², Marc de Longueville², Cathy O'Brien² and Ermis Parussini³, ¹Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France, ²UCB Pharma, Brussels, Belgium, ³Theradiag, Croissy-Beaubourg, France
Background/Purpose: Measurement of plasma anti-TNF concentration, in combination with the assessment of clinical outcomes, may be used to optimize dosing regimens for individual patients (pts).…
Abstract Number: 821 • 2015 ACR/ARHP Annual Meeting
Elevated Serum Levels of Soluble CD146 in Patients with Systemic Sclerosis
Kazunori Kato¹, Tomoko Ito², Naoto Tamura², Sayuri Okuda¹, Masakazu Matsushita², Kurisu Tada², Ken Yamaji² and Yoshinari Takasaki², ¹Department of Biomedical Engineering, Toyo University, Saitama, Japan, ²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: CD146 is a transmembrane glycoprotein belonging to Ig-superfamily. Human endothelial cells, activated fibroblasts and Th17 cells express CD146 that involved in angiogenesis, fibrosis and…
Abstract Number: 1258 • 2014 ACR/ARHP Annual Meeting
Enzyme-Linked Immunosorbent Assays for Detection of Anti-Transcriptional Intermediary Factor-1 Gamma and Anti-Mi-2 Autoantibodies in Dermatomyositis: Utility and Crossreactivity
Manabu Fujimoto¹, Akihiro Murakami², Shunsuke Kurei², Akiko Kuwajima³, Yasuhiro Fujisawa¹, Atsushi Kawakami⁴, Michiaki Mishima⁵, Shinji Sato⁶, Mariko Seishima⁷, Takafumi Suda⁸, Tsuneyo Mimori⁹, Kazuhiko Takehara¹⁰ and Masataka Kuwana¹¹, ¹Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Medical & Biological Laboratories Co., Ltd, Nagaya, Japan, ³Medical & Biological Laboratories Co.,Ltd., Nagoya, Japan, ⁴Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Japan, ⁶Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ⁷Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan, ⁸Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan, ⁹Dept of Rheum & Clinical Immunology, Kyoto Univ Grad Schl of Med, Kyoto, Japan, ¹⁰Dermatology, Kanazawa University, Kanazawa, Japan, ¹¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Anti-transcriptional intermediary factor 1 (TIF-1) and anti-Mi-2 antibodies (Abs) are myositis-specific autoantibodies (MSA) selectively detected in dernatomyositis (DM) patients. Anti-TIF-1 Ab is frequently found…
Abstract Number: 648 • 2013 ACR/ARHP Annual Meeting
A Possible Contribution of Inducible Costimulator to the Development of Skin Sclerosis and Interstitial Lung Disease in Systemic Sclerosis
Koichi Yanaba¹, Yoshihide Asano² and Shinichi Sato², ¹Dermatology, The University of Tokyo, Tokyo, Japan, ²Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous disorder characterized by excessive fibrosis and microvascular damage of the skin and various internal organs. Cutaneous mononuclear cell…
Abstract Number: 26 • 2013 ACR/ARHP Annual Meeting
Autoantibodies Directed Against Cell Surface Components In Autoimmune Disease Patients: Proposal Of a Novel ELISA For The Detection Of Anti-Endothelial Cell Antibodies
Keiji Miura¹, Ayako Kondo², Kazuo Takahashi², Daisuke Hirano², Yoshiyuki Hiki³, Shunji Yoshida², Yukio Yuzawa² and Yoshikazu Kurosawa³, ¹Institute for Comprehensive Medical Science, Fujita Health Universtiy, Toyoake, Japan, ²Fujita Health Universtiy School of Medicine, Toyoake, Japan, ³Fujita Health Universtiy, Toyoake, Japan
Background/Purpose: Sera from patients with systemic vasculitis or inflammatory conditions have been reported to contain antibodies that bind to endothelial cells (EC), i.e., AECA (anti-endothelial…
Abstract Number: 1536 • 2012 ACR/ARHP Annual Meeting
Clinical Features of Patients with Anti-Neutrophil Cytoplasmic Autoantibodies Targeting Native Myeloperoxidase Antigen
Yuji Yamanishi¹, Toshiko Ito-Ihara², Shigeto Kobayashi³, Peter Y. Shane⁴, Gary S. Firestein⁵, Hiroshi Hashimoto⁶ and Kazuo Suzuki⁷, ¹Division of Rheumatology, Hiroshima Rheumatology Clinic, Hiroshima, Japan, ²Department of Clinical Innovative Medicine, Translational Research Center, Kyoto University Hospital, Kyoto, Japan, ³Department of Internal Medicine, Juntendo University Koshigaya Hospital, Tokyo, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Div of Rheumatology, UCSD School of Medicine, La Jolla, CA, ⁶Juntendo Tokyo Koto Geriatric Center, Tokyo, Japan, ⁷National Institute of Infectious Diseases, Tokyo, Japan
Background/Purpose: ANCA is a useful diagnostic marker in systemic vasculitic disorders with small-vessel involvement, but depending on the particular test used the myeloperoxidase (MPO)-ANCA results…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].